BC Extra | Sep 27, 2019
Politics & Policy

China unveils three-year plan for cancer prevention, control

China’s 2019-22 cancer prevention and control plan broadly outlines measures the country plans to take to standardize screening and treatment, improve access to cancer drugs and accelerate review of HPV vaccines. The plan, released Monday,...
BC Extra | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
BC Extra | Mar 1, 2019
Company News

Ex-Merck China R&D head joins Ascletis as CMO

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Zhengqing Li as CMO and president of R&D Greater China. He was global VP of MSD China and general manager of the Merck & Co. Inc....
BC Week In Review | Jun 1, 2018
Company News

Chinese investors launch HPV JV

Shanghai Institute of Biological Products Co. Ltd. (Shanghai, China), 6 Dimensions Capital and Renxian Bioscience Co. Ltd. launched a JV -- Shanghai Zhicheng Bioscience Co. Ltd. -- to develop quadrivalent HPV vaccines in China. The...
BC Extra | May 25, 2018
Company News

Chinese investors launch HPV JV

Shanghai Institute of Biological Products Co. Ltd. (Shanghai, China), 6 Dimensions Capital and Renxian Bioscience Co. Ltd. launched a JV -- Shanghai Zhicheng Bioscience Co. Ltd. -- to develop quadrivalent HPV vaccines in China. The...
BioCentury | Sep 7, 2017
Strategy

What if you build, but they don’t come

Vaccination is widely considered one of the greatest medical achievements of modern civilization. Diseases that were commonplace less than a generation ago, such as polio, smallpox and diphtheria, are now increasingly rare because of vaccines....
BC Week In Review | Jan 4, 2016
Clinical News

Gardasil 9 regulatory update

FDA approved Merck’s Gardasil 9 HPV vaccine for use in males ages 16-26. The recombinant HPV vaccine is already marketed in males ages 9-15 and females ages 9-26 to prevent anal cancer caused by HPV...
BC Innovations | Nov 19, 2015
Product R&D

Bugs against chlamydia

Synthetic biology company Prokarium Ltd. is creating oral vaccines based on a bacterial system that produces a wider range of antigens and fewer side effects than injectables. With its goal to produce the first vaccine...
BC Week In Review | Aug 17, 2015
Clinical News

Gardasil 9 regulatory update

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began a safety review of human papillomavirus (HPV) vaccines, including Gardasil 9. PRAC will review rare reports of complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome to...
BC Week In Review | Jun 29, 2015
Clinical News

Gardasil 9 regulatory update

The European Commission approved Gardasil 9 from Merck to prevent cancers caused by 9 HPV types in children ages >=9. Specifically, the recombinant HPV vaccine against types 6, 11, 16, 18, 31, 33, 45, 52...
Items per page:
1 - 10 of 21